Meshconomy

Pulsight

Wearable medical patch assessing vital signs during trauma

Israel

1-10

Vitality Radar

Current

Industry

Updated 24 days ago

Pillar Analysis

Presence

Digital footprint, brand visibility, and online reach across channels

Business

Revenue signals, funding status, partnerships, and market traction

Innovation

R&D activity, patents, product launches, and technology adoption

Pulse

Recent momentum — hiring trends, news mentions, and social engagement

Capacity

Team strength, leadership depth, and organizational scale

Strategic Assessment

Strategic Vector

PulseSight Therapeutics is advancing non-viral gene therapies for ophthalmology, focusing on age-related macular degeneration (AMD) including wet AMD and geographic atrophy via a proprietary electro-transfection delivery platform already validated in Phase I/II trials.

Efficiency Ratio

High efficiency demonstrated by rapid progression from 2024 launch to Phase 1 completion in 2026 with seed/Series A funding supporting clinical milestones.

Evidence Signals

Product Launch HIGH Paris, France

Completed Phase 1 dosing of gene therapy candidate PST-611 for dry AMD and geographic atrophy.

View source

Product Launch HIGH Paris, France

Completed enrollment in gene therapy trial and key safety trial for novel dry AMD gene therapy.

View source

Funding HIGH Paris, France

Launched with seed financing from Pureos Bioventures and ND Capital; Series A first close announced.

View source

Leadership Change HIGH Paris, France

Appointed Judith Greciet as CEO and Dirk Sauer as Independent Chair of the Board.

View source

Partnership HIGH Paris, France

Backed by investors Pureos Bioventures, ND Capital, and Korea Investment Partners with board representation.

View source

Expansion HIGH Paris, France

Company founded in 2024 and progressed to clinical-stage with platform validated in prior Phase I/II study.

View source

Other HIGH Paris, France

IP portfolio includes 11 patent families with 90 granted patents covering non-viral gene therapy platform.

View source

About: Pulsight develops an innovative, wearable neck patch that rapidly assesses vital signs for trauma victims. The device assists military medics in prioritizing care during mass-casualty events on the battlefield by quickly triaging patients and enabling faster life-saving treatments.
Tags

Suggest an edit